https://www.nature.com/articles/d41591-023-00067-x
0
0
7/31/23 at 10:30am
Organization
Nature.com
29 words
0
Comments
The monoclonal antibody donanemab, which clears amyloid plaques in the brain, slowed clinical progression of early symptomatic Alzheimer’s disease.
You are the first to view
Create an account
or login to join the discussion